Literature DB >> 12050253

Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study.

Claus Højbjerg Gravholt1, Anna Lis Lauridsen, Kim Brixen, Leif Mosekilde, Lene Heickendorff, Jens Sandahl Christiansen.   

Abstract

Most women with Turner syndrome (TS) have no gonadal activity and thus lack estrogen. Bone mineral density (BMD) is often reduced, leading to an increased risk of osteoporosis and fractures. However, growth retardation with reduced final height and other endocrine disturbances may compromise interpretation of skeletal measurements. The aim of the present study was to explore skeletal findings, bone metabolism, and calcium homeostasis in TS. Sixty women with TS (age, 37 +/- 9 yr) and 181 normal age-matched female controls were studied. Bone area (A; square centimeters), bone mineral content (BMC; grams), area-adjusted BMD (aBMD; grams/square centimeter), and volumetric BMD (vBMD; grams/cubic centimeter) were measured at lumbar spine, femoral neck, and forearm using dual energy x-ray absorptiometry. Twenty-eight percent had osteopenia, and 23% had osteoporosis, according to World Health Organization criteria. At the lumbar spine, A, BMC, aBMD, and vBMD were reduced by 18, 27, 11, and 6%, respectively; at the femoral neck, A, BMC, and aBMD were reduced by 2, 10, and 8%, respectively, whereas the 9% reduction in vBMD was insignificant (P = 0.07); and in the forearm, A, BMC, and aBMD were reduced by 53, 55, and 9%, respectively. Bone markers indicated an enhanced bone resorption (21 and 23% increase in C-terminal and N-terminal cross-linking telopeptides of type I collagen/creatinine, respectively) with unchanged (osteocalcin, procollagen I N-terminal propeptide) or reduced (54% reduction in bone alkaline phosphatase) bone formation. Plasma levels of calcium and 25-hydroxyvitamin D (26%) were reduced, and PTH levels increased (74%) in TS. IGF-I (30%), IGF binding protein 3 (18%), testosterone (50%), and SHBG (40%) were reduced in TS. In summary, A, BMC, and aBMD were found to be universally reduced in TS, whereas vBMD was slightly reduced in the spine. Increased resorption of bone was present, with normal or blunted bone formation, suggesting uncoupling or imbalance in bone remodeling. Skeletal changes may be induced by chromosome abnormalities or by secondary endocrine or metabolic changes related to a relative estrogen deficiency, testosterone deficiency, reduced IGF-I, low vitamin D status, and secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050253     DOI: 10.1210/jcem.87.6.8598

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Bone mineral mass in males and females with and without Down syndrome.

Authors:  Fatima Baptista; Ana Varela; Luis B Sardinha
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

Review 2.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 3.  Effects of hypogonadism on bone metabolism in female adolescents and young adults.

Authors:  Madhusmita Misra
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

Review 4.  New issues in the diagnosis and management of Turner syndrome.

Authors:  Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 5.  Bone mineral accrual and low bone mass: a pediatric perspective.

Authors:  Inessa M Gelfand; Linda A DiMeglio
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

6.  Artificially low cortical bone mineral density in Turner syndrome is due to the partial volume effect.

Authors:  O Soucek; E Schönau; J Lebl; Z Sumnik
Journal:  Osteoporos Int       Date:  2014-10-07       Impact factor: 4.507

7.  Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.

Authors:  Adrian G Ruetsche; Renato Kneubuehl; Martin H Birkhaeuser; Kurt Lippuner
Journal:  Osteoporos Int       Date:  2004-10-16       Impact factor: 4.507

8.  Bone mass in male and female children and adolescents with Down syndrome.

Authors:  A González-Agüero; G Vicente-Rodríguez; L A Moreno; J A Casajús
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

9.  Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome.

Authors:  L Torres-Santiago; V Mericq; M Taboada; N Unanue; K O Klein; R Singh; J Hossain; R J Santen; J L Ross; N Mauras
Journal:  J Clin Endocrinol Metab       Date:  2013-05-15       Impact factor: 5.958

Review 10.  Fracture risk and bone mineral density in Turner syndrome.

Authors:  Vladimir K Bakalov; Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2008-04-15       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.